Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: Weight loss is often nonsustainable after liraglutide cessation. The present study is the first insight into the potential prevention of weight regain in obese subjects who have been withdrawn from liraglutide. We evaluated whether dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin in adjunct to metformin prevents body weight regain more effectively than metformin alone in obese polycystic ovary syndrome (PCOS) previously treated with liraglutide. Methods: A 12-week prospective randomized open-label study was conducted with 24 obese women with PCOS who had been pretreated with liraglutide 3.0 mg due to antiobesity management (aged 34.3 ± 6.8 years, body mass index [BMI] 36.3 ± 5.2 kg/m2, mean ± standard deviation). They were randomized to combined treatment (COMBO) with sitagliptin 100 mg per day (QD) and metformin (MET) 1000 mg twice daily (BID) (n = 12) or MET 1000 mg BID (n = 12). Lifestyle intervention was promoted in both groups. The primary outcome was change in anthropometric measures of obesity. Results: Women treated with MET regain 4.7 ± 2.7 kg (P = 0.002) compared with a 0.9 ± 2.5 kg in COMBO (P = 0.147). BMI increased for 1.7 ± 0.9 kg/m2 in MET (P = 0.002) compared with 0.3 ± 0.8 kg/m2 increase in COMBO (P = 0.136). MET group regain 4.5% ± 2.5% of body weight as opposed to 0.8% ± 2.6% in COMBO. The between-treatment differences were significant for weight change (P < 0.001), percentage of weight change (P < 0.001), and BMI change (P < 0.001). Greater ability to resist emotional eating was demonstrated in COMBO. Conclusion: Sitagliptin in adjunct to metformin prevented weight regain in obese women with PCOS previously treated with liraglutide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 2×
“Longitudinal observations reported that maximum rates of weight loss were achieved in the initial 20-week treatment period with a weight maintenance and even tendency toward weight gain beyond 36 weeks.(2,11) This might be due to the development of treatment resistance, most apparent after 36 weeks from initiation.”
Backgroundle Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850 · cited 1×
“5% weight loss over 1 year and became an established antiobesity treatment.(2,3) Its effect on body weight appears to be due to reduction in food intake, mainly by a direct central effect and partly by delay of gastric emptying.”
Backgroundon behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · cited 2×
“Longitudinal observations reported that maximum rates of weight loss were achieved in the initial 20-week treatment period with a weight maintenance and even tendency toward weight gain beyond 36 weeks.(2,11) This might be due to the development of treatment resistance, most apparent after 36 weeks from initiation.”
BackgroundElkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0115 · Cited by 276
Jensterle, M., Kravos, N. A., Pfeifer, M., Kocjan, T., & Janez, A. (2015) · Hormones · doi:10.1007/bf03401383 · Cited by 117
Self-citation
Research works printed but not linked: 25
- 10.1111/dom.12119 · DOI · Paper page
- 10.1177/2040622315620180 · DOI · Paper page
- 10.1186/1475-2840-11-107 · DOI
- 10.1016/j.ejphar.2014.08.010 · DOI
- 10.2174/1381612822666160715143933 · DOI · Paper page
- 10.1530/EJE-13-0797 · DOI · Paper page
- 10.4239/wjd.v7.i20.572 · DOI
- DeFronzo R, 2014, Diabetologia, 57, 38
- 10.1007/s00125-015-3754-x · DOI · Paper page
- 10.1001/jama.2010.405 · DOI · Paper page
- 10.1016/j.clinthera.2012.04.013 · DOI · Paper page
- 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
- 10.2337/db13-1455 · DOI
- de Lauzon B, 2004, J Nutr, 134, 2372, 10.1093/jn/134.9.2372 · DOI · Paper page
- 10.1046/j.1464-5491.2000.00280.x · DOI · Paper page
- 10.1016/0022-3999(85)90010-8 · DOI · Paper page
- Vickers SP, 2012, Clin Lab, 58, 787
- 10.1186/s12876-016-0560-y · DOI · Paper page
- 10.2147/VHRM.S10952 · DOI · Paper page
- 10.1053/j.gastro.2003.11.007 · DOI · Paper page
- 10.1016/S1542-3565(05)00285-5 · DOI
- 10.1007/s11695-007-9031-4 · DOI
- Wright RA, 1983, Gastroenterology, 84, 747, 10.1016/0016-5085(83)90141-5 · DOI · Paper page
- Tosetti C, 1996, Int J Obes Relat Metab Disord, 20, 200
- 10.1007/BF01249617 · DOI
Cited by
West, S., Scragg, J., Aveyard, P., Oke, J. L., Willis, L., Haffner, S. J. P., Knight, H., Wang, D., Morrow, S., Heath, L., et al. (2026) · BMJ · doi:10.1136/bmj-2025-085304 · Cited by 174
“In most studies, the support provided after the WMM ended was identical except for two studies, where authors compared metformin with no metformin 28 and behavioural support with no behavioural support.”
Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., & Scaroni, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249554 · Cited by 36
Current and emerging drug treatment strategies for polycystic ovary syndrome
Helvaci, N., & Yildiz, B. O. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2108702 · Cited by 35
“Sitagliptin was associated with a significant decrease in the maximal glucose response to OGTT and level of total cholesterol but was not superior to placebo in improving other metabolic and hormonal parameters including fasting glucose, fasting insulin, HOMA-IR, and total testosterone [83].”
BackgroundInfluentialLiraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome
Papaetis, G. S., Filippou, P. K., Constantinidou, K. G., & Stylianou, C. S. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00942-2 · Cited by 25
Medical Treatment and Comorbidity in Polycystic Ovary Syndrome: An Updated Review
Glintborg, D., & Andersen, M. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.02.014 · Cited by 20
Metadata
- Authors
- Ferjan, S., Janez, A., & Jensterle, M.
- Venue
- Metabolic Syndrome and Related Disorders
- Publisher
- SAGE Publications
- Published
- 2017-12
- Volume
- 15
- Issue
- 10
- Pages
- 515-520
- ISSN
- 1540-4196 (ISSN-L)
- 1557-8518
- OpenAlex
- W2765217575
- Cited by
- 36
- References
- 6
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study. https://app.cochat.ai/papers/10.1089/met.2017.0095
- The paper
- Ferjan, S., Janez, A., & Jensterle, M. (2017). Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study. Metabolic Syndrome and Related Disorders. https://doi.org/10.1089/met.2017.0095
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.